Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Breast Neoplasms 145Stomach Neoplasms 22Triple Negative Breast Neoplasms 21Inflammatory Breast Neoplasms 14Carcinoma, Hepatocellular 13Esophageal Neoplasms 11Lymphoma, Large B-Cell, Diffuse 7Neoplasms 6Pancreatic Neoplasms 5Urinary Bladder Neoplasms 4Adenocarcinoma Of Esophagus 4Testicular Neoplasms 3Sarcoma 3Primary Breast Cancer 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Non-Muscle Invasive Bladder Neoplasms 3Liver Neoplasms 3Gallbladder Neoplasms 3Carcinoma, Ductal, Breast 3Breast Neoplasms, Male 3Unspecified Adult Solid Tumor, Protocol Specific 2Recurrence 2Pathologic Complete Response 2Neoplastic Cells, Circulating 2Neoplasms, Germ Cell and Embryonal 2HER2-negative Breast Cancer 2Carcinoma, Adenoid Cystic 2Breast Diseases 2pCR Rate 1Women With Primary Breast Cancer 1

Interventions

Dexamethasone 420Lenalidomide 265Cyclophosphamide 246Bortezomib 242Melphalan 192Calcium Dobesilate 166fludarabine phosphate 112daratumumab 103Peripheral Blood Stem Cell Transplantation 99carfilzomib 92Thalidomide 90Filgrastim 88Mycophenolic Acid 82fludarabine 81pomalidomide 80Whole-Body Irradiation 80Busulfan 74Tacrolimus 71Granulocyte Colony-Stimulating Factor 66Cyclosporine 58dexamethasone acetate 56ixazomib 55Antilymphocyte Serum 50dexamethasone 21-phosphate 49auricularum 44isatuximab 40Etoposide 39Radiotherapy 36Stem Cell Transplantation 34Methotrexate 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Multiple Myeloma × Epirubicin × Clear all
NCT06140966 2025-04-16

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Recruiting
54 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡